Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | Highlights from WSC 2023

Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Ontario, Canada, shares his highlights from the World Stroke Congress (WSC) 2023 in Toronto, Canada. Dr Katsanos mentions the CHANCE-3 (NCT05439356) trial, investigating the efficacy of anti-inflammatory drug colchicine in reducing repeat stroke risk. The results from ESCAPE-NEXT (NCT04462536) and FRONTIER (NCT02315443) were also presented at WSC 2023, which assessed the efficacy of nerinetide in reducing global disability in patients with acute cerebral ischemia. The Phase IV trial ANNEXA-I (NCT03661528) was another highlight, showing overwhelming efficacy of andexanet alfa in reducing hematoma size during anticoagulation-associated intracranial hemorrhage. The presented findings sparked discussions amongst researchers on the most effective strategies to translate discoveries into clinical practice. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.